戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1        peT(H)2 but not cT(H)2 cells produced prostaglandin D2.
2 vage fluid (BALF) contain elevated levels of prostaglandin D2.
3 alpha, prostaglandin I2, thromboxane A2, and prostaglandin D2.
4 ase of the mast cell mediators histamine and prostaglandin D2.
5 pase D, which can increase the production of prostaglandin D2.
6 erbation was associated with reduced exudate prostaglandin D2 and 15deoxy delta(12-14)prostaglandin J
7 ng, resulting in the synthesis of 15R-methyl prostaglandin D2 and allows rapid access to other prosta
8  results from GPR109A-mediated production of prostaglandin D2 and E2 in Langerhans' cells which act o
9                                Median sputum prostaglandin D2 and prostaglandin E2 concentrations wer
10 tamine, cysteinyl-leukotrienes, prostanoids (prostaglandin D2 and prostaglandin E2), and interleukin-
11  T cells highly express Cox-2 and synthesize prostaglandin D2 and related prostaglandins that are PPA
12 nd release of arachidonate, the precursor of prostaglandin D2 and the vasodilator responsible for the
13 r prostanoids: prostacyclin, thromboxane A2, prostaglandin D2, and 12-hydroxyheptadecatrienoic acid.
14                       In contrast, levels of prostaglandin D2, and 15deoxy delta(12-14)prostaglandin
15          Bronchoalveolar lavage fluid cells, prostaglandin D2, and cysteinyl leukotrienes from hyperv
16 ls, along with increased production of IL-5, prostaglandin D2, and eosinophil and T-helper type 2 cel
17              Release of beta-hexosaminidase, prostaglandin D2, and GM-CSF and changes in reactive oxy
18 ors (histamine, serotonin, leukotriene C(4), prostaglandin D2, and mouse mast cell protease 1) were q
19 enase-activating protein, 15-lipoxygenase-1, prostaglandin D2, and proinflammatory cytokines.
20 tabolites of prostacyclin, prostaglandin E2, prostaglandin D2, and thromboxane A2 were also reduced.
21 id pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eico
22 ocation, showing increases in metabolites of prostaglandin D2, cysteinyl leukotrienes, and isoprostan
23            AGN 211377 antagonizes prostanoid prostaglandin D2 (DP)1, DP2, prostaglandin E2 (EP)1, EP4
24              We have reported that bioactive prostaglandin D2/E2-like compounds, termed D2/E2-isopros
25 on pathways mediating the anti-lipolytic and prostaglandin D2/flushing pathways are distinct and that
26 ect appears to be mediated by the release of prostaglandin D2 from Langerhans cells in the skin.
27 nase-2 to give rise to the anti-inflammatory prostaglandin D2-glycerol ester (PGD2-G).
28 er than twice the upper limit of normal) and prostaglandin D2 (>3.4 times the upper limit of normal)
29                                              Prostaglandin D2 has been established as promoting the r
30                                              Prostaglandin D2 has been shown to have growth inhibitor
31                                              Prostaglandin D2 levels were measured with ELISA.
32 been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids,
33  induced a dose-related reduction in ex vivo prostaglandin D2-mediated eosinophil shape change.
34           Although it has been reported that prostaglandin D2 mediates allergic inflammation via its
35                                        Basal prostaglandin D2 metabolite (PGD-M; 13.6 +/- 2.7 vs 7.0
36 urring compounds such as fatty acids and the prostaglandin D2 metabolite 15-deoxy-delta prostaglandin
37 strogen treatment induced the formation of a prostaglandin D2 metabolite that activated duck PPARgamm
38 suggest that PPAR-gamma and locally produced prostaglandin D2 metabolites are involved in the regulat
39                                              Prostaglandin D2 metabolites have not yet been identifie
40 selective DP2 agonist 13, 14-dihydro-15-keto prostaglandin D2 on epithelial cell migration and differ
41 04418948, but not by the antagonists of EP4, prostaglandin D2, or prostacyclin receptors.
42 set of patients with AERD is associated with prostaglandin D2 overproduction.
43 at Ptgds encodes the enzyme that synthesizes prostaglandin D2 (PGD(2)), we further explored its role
44                                              Prostaglandin D2 (PGD2 ) plays an important role in alle
45                                              Prostaglandin D2 (PGD2) acting at the CRTH2 receptor (ch
46                                              Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysL
47                              Also, levels of prostaglandin D2 (PGD2) and lipoxin A4 (LXA4) in patient
48                    Arachidonic acid (AA) and prostaglandin D2 (PGD2) as well as some of the lysophosp
49              Effects of common pesticides on prostaglandin D2 (PGD2) inhibition in SC5 mouse Sertoli
50                                              Prostaglandin D2 (PGD2) is an extensively studied sleep-
51 ks provide evidence of the importance of the prostaglandin D2 (PGD2) metabolic pathway in inflammator
52 n-type prostaglandin D synthase (L-PGDS) and prostaglandin D2 (PGD2) metabolites produced by normal p
53              In contrast, the time course of prostaglandin D2 (PGD2) or 9 alpha, 11 beta PGF2 (11 bet
54 a,beta-unsaturated ene acid 1-E to give 2, a prostaglandin D2 (PGD2) receptor antagonist.
55     Here, we show that mice deficient in the prostaglandin D2 (PGD2) receptor CRTH2 and mice with CRT
56    We show in this paper that lipocalin-type prostaglandin D2 (PGD2) synthase (L-PGDS) interacts intr
57                                              Prostaglandin D2 (PGD2) synthesis in activated mast cell
58 monly used in the European Union to suppress prostaglandin D2 (PGD2) synthesis.
59 motaxis of inflammatory cells in response to prostaglandin D2 (PGD2), is hypothesized to play a role
60  niacin provokes Langerhans cells to produce prostaglandin D2 (PGD2), stimulating vascular DP1 recept
61                Furthermore, we also show how prostaglandin D2 (PGD2), which is upregulated in balding
62 arasitic infections, leads to the release of prostaglandin D2 (PGD2).
63 activation, including abundant production of prostaglandin D2 (PGD2).
64 a), prostaglandin F(2alpha) (PGF2alpha), and prostaglandin D2 (PGD2).
65 line, induces the synthesis and secretion of prostaglandin D2 (PGD2).
66 mphopoietin [TSLP]) and mast cell mediators (prostaglandin D2 [PGD2]) are critical activators of ILC2
67 ible and competitive with the native agonist prostaglandin D2(PGD2).
68 ed in combination with niacin to abolish the prostaglandin D2-(PGD2)-induced flushing.
69 amster ovary cells and permits chemokine and prostaglandin D2 production by LAD2 cells, a human mast
70 esulted in over 50% decrease in KLA-elicited prostaglandin D2 production.
71                       13, 14-Dihydro-15-keto prostaglandin D2 promoted epithelial cell migration and
72 excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and Ntau-methylhistamine (r
73 circulated human CD4+ T cells expressing the prostaglandin D2 receptor (CRTH2) are TH2 central memory
74                                          The prostaglandin D2 receptor 1 (DP1), a member of the prost
75            Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates ni
76  that fevipiprant (QAW039), an antagonist of prostaglandin D2 receptor 2, might reduce eosinophilic a
77  histocompatibility complex type II, and the prostaglandin D2 receptor CD294, all normally associated
78 gic rhinitis (SAR) is partly mediated by the prostaglandin D2 receptor chemoattractant receptor homol
79 mokine receptor CCR5 (Th1/Tc1-specific), and prostaglandin D2 receptor CRTH2 (Th2/Tc2-specific).
80 identified prostaglandin E2 receptor EP2 and prostaglandin D2 receptor DP as responsive to OxPAPC.
81           GB001 is an oral antagonist of the prostaglandin D2 receptor that may inhibit recruitment a
82 econd intron of the thromboxane A2 receptor, prostaglandin D2 receptor, prostaglandin I2 receptor, an
83 d, compound 1 (AGN 211377), that antagonizes prostaglandin D2 receptors (DPs) DP1 (49) and DP2 (558),
84 ect the functional consequences of decreased prostaglandin D2 release and the therapeutic benefit of
85 ession, activation, cytokine, histamine, and prostaglandin D2 release, and performed transcriptomics
86                               Lipocalin-type prostaglandin D2 synthase (L-PGDS) has recently been lin
87  dehydrogenase 2 (RALDH2) and lipocalin-type prostaglandin D2 synthase (LPGDS), which, respectively,
88 ied in human meningiomas with the use of the prostaglandin D2 synthase (PGDS) promoter.
89 g growth factor beta receptor 3 (TGFBR3) and prostaglandin D2 synthase (PTGDS) had the strongest asso
90                 Among them, KRT7, KRT19, and prostaglandin D2 synthase (PTGDS) were significantly dow
91           The levels of WIHN, lipocalin-type prostaglandin D2 synthase (Ptgds), and its product PGD2
92                                 In contrast, prostaglandin D2 synthase declined during late torpor an
93 ed lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase with an MRA.
94 matrix metalloproteinase 11, integrin beta2, prostaglandin D2 synthase, and interleukin-1 receptor an
95 tatin A, Charcot-Leydon crystal protein, and prostaglandin D2 synthase, implying their broader roles
96                        betaTP, also known as prostaglandin D2 synthase, is a lipocalin secreted from
97 nhibitors, galectins, osteonectin/SPARC, and prostaglandin D2 synthase.
98 ibited antigen-induced PMC degranulation and prostaglandin D2 synthesis in vitro.
99 andin-J2 (delta 12-PG J2) is a derivative of prostaglandin D2 that has been shown to have similar inh
100                                Conversion of prostaglandin D2 to a metabolite was induced by estradio
101 andin J2, whereas under the same conditions, prostaglandin D2 was not effective.
102                It is the second receptor for Prostaglandin D2, whose activation leads to chemotaxis a

 
Page Top